Clinical Trials Logo

Phobic Disorders clinical trials

View clinical trials related to Phobic Disorders.

Filter by:

NCT ID: NCT00051220 Completed - Anxiety Disorders Clinical Trials

Treatment for Specific Phobias in Children

Start date: October 2001
Phase: Phase 1/Phase 2
Study type: Interventional

This study will compare the effectiveness of three treatments in reducing symptoms of phobia in children and adolescents.

NCT ID: NCT00043537 Completed - Social Phobia Clinical Trials

Treatment of Childhood Social Phobia

Start date: April 2001
Phase: Phase 3
Study type: Interventional

This 4-year study will compare the long-term effectiveness of behavioral treatment, fluoxetine (Prozac®), and placebo for treatment of social phobia in children and adolescents.

NCT ID: NCT00035412 Completed - Phobic Disorders Clinical Trials

St. John's Wort Versus Placebo in Social Phobia

Start date: December 2001
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness of St. John’s Wort as compared to placebo (an inactive substance) in the treatment of outpatients with social phobia.

NCT ID: NCT00000370 Completed - Social Phobia Clinical Trials

Treatment of Social Phobia

Start date: May 1998
Phase: N/A
Study type: Interventional

Social phobia is a very common and debilitating disorder, with public speaking anxiety being the most common fear. Psychologists have found that treating patients for their fear of public speaking, through cognitive-behavioral treatment (talk-based therapy) or exposure treatment (where participants participate in actual public speaking sessions), not only helps patients overcome this fear but also helps them overcome their more general social fears. However, little is known about how this change occurs during therapy. This study tries to identify the factors that contribute most to successful therapy. Patients are assigned randomly (like tossing a coin) to 1 of 3 groups. Group 1 will receive cognitive-behavioral treatment and Group 2 will receive exposure treatment. Group 3 will not receive treatment. Study leaders will monitor patient response to treatment through behavioral tests and assessments. An individual may be eligible for this study if he/she: Has social phobia with public speaking anxiety.